FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2161844504> ?p ?o ?g. }

• W2161844504 endingPage "1529" @default.
• W2161844504 startingPage "1525" @default.
• W2161844504 abstract "The role of donor lymphocyte infusion (DLI) in mediating the graft-versus-myeloma (GvM) effect after allogeneic hematopoietic stem cell transplant (allo-HCT) is not clearly defined. We evaluated the safety and utility of DLI in patients with either persistent or recurrent multiple myeloma (MM) after allo-HCT. Twenty-three patients with MM received DLI after allo-HCT at the University of Texas M. D. Anderson Cancer Center between July 1996 and June 2008. Eight patients received preemptive DLI for residual disease (RD) while 15 patients received DLI for the treatment of recurrent or progressive disease (PD). We evaluated the response to DLI and the factors that may predict a response. Median DLI dose was 3.3 × 10(7) CD3 + cells (range 0.5-14.8 × 10(7)). Grade II-IV acute graft-versus-host disease (GvHD) was seen in five patients (22%). Median follow-up in surviving patients was 24 months. Five of 23 patients (22%) achieved a complete or a very good partial response (two CR, three VGPR), while eight patients (34%) had stable disease (SD) after the DLI. Patients who received DLI for RD had a higher response rate (≥ VGPR 50% vs. 7%, p = 0.03), a longer overall survival (28.3 vs. 7.6 months, p = 0.03) and a trend toward longer progression-free survival (11.9 vs. 5.2 months, p = 0.1). In this largest single institution study, we conclude that the use of preemptive, non-manipulated DLI for RD after reduced-intensity conditioning allo-HCT is encouraging, and it was associated with a higher response rate and a longer overall survival when given preemptively. The role of DLI needs to be further explored in prospective clinical trials." @default.
• W2161844504 created "2016-06-24" @default.
• W2161844504 creator A5015342719 @default.
• W2161844504 creator A5016928938 @default.
• W2161844504 creator A5026422612 @default.
• W2161844504 creator A5038261300 @default.
• W2161844504 creator A5040975741 @default.
• W2161844504 creator A5047522685 @default.
• W2161844504 creator A5048913229 @default.
• W2161844504 creator A5050962913 @default.
• W2161844504 creator A5053904944 @default.
• W2161844504 creator A5065998208 @default.
• W2161844504 creator A5066894053 @default.
• W2161844504 creator A5068834306 @default.
• W2161844504 creator A5070096873 @default.
• W2161844504 creator A5083279961 @default.
• W2161844504 date "2012-03-01" @default.
• W2161844504 modified "2023-10-02" @default.
• W2161844504 title "Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant" @default.
• W2161844504 cites W121638319 @default.
• W2161844504 cites W1530764705 @default.
• W2161844504 cites W1539005347 @default.
• W2161844504 cites W1545991364 @default.
• W2161844504 cites W1589162162 @default.
• W2161844504 cites W1977691688 @default.
• W2161844504 cites W1977950751 @default.
• W2161844504 cites W1988866710 @default.
• W2161844504 cites W2010012376 @default.
• W2161844504 cites W2010766702 @default.
• W2161844504 cites W2034771855 @default.
• W2161844504 cites W2040650332 @default.
• W2161844504 cites W2044186255 @default.
• W2161844504 cites W2053700269 @default.
• W2161844504 cites W2057831000 @default.
• W2161844504 cites W2069519666 @default.
• W2161844504 cites W2075729465 @default.
• W2161844504 cites W2114438875 @default.
• W2161844504 cites W2122021478 @default.
• W2161844504 cites W2124116840 @default.
• W2161844504 cites W2141451077 @default.
• W2161844504 cites W2161702482 @default.
• W2161844504 cites W2171832779 @default.
• W2161844504 cites W2255034921 @default.
• W2161844504 cites W2324565208 @default.
• W2161844504 cites W2325022302 @default.
• W2161844504 doi "https://doi.org/10.3109/10428194.2012.656635" @default.
• W2161844504 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22242817" @default.
• W2161844504 hasPublicationYear "2012" @default.
• W2161844504 type Work @default.
• W2161844504 sameAs 2161844504 @default.
• W2161844504 citedByCount "24" @default.
• W2161844504 countsByYear W21618445042013 @default.
• W2161844504 countsByYear W21618445042014 @default.
• W2161844504 countsByYear W21618445042015 @default.
• W2161844504 countsByYear W21618445042016 @default.
• W2161844504 countsByYear W21618445042017 @default.
• W2161844504 countsByYear W21618445042018 @default.
• W2161844504 countsByYear W21618445042019 @default.
• W2161844504 countsByYear W21618445042020 @default.
• W2161844504 countsByYear W21618445042021 @default.
• W2161844504 crossrefType "journal-article" @default.
• W2161844504 hasAuthorship W2161844504A5015342719 @default.
• W2161844504 hasAuthorship W2161844504A5016928938 @default.
• W2161844504 hasAuthorship W2161844504A5026422612 @default.
• W2161844504 hasAuthorship W2161844504A5038261300 @default.
• W2161844504 hasAuthorship W2161844504A5040975741 @default.
• W2161844504 hasAuthorship W2161844504A5047522685 @default.
• W2161844504 hasAuthorship W2161844504A5048913229 @default.
• W2161844504 hasAuthorship W2161844504A5050962913 @default.
• W2161844504 hasAuthorship W2161844504A5053904944 @default.
• W2161844504 hasAuthorship W2161844504A5065998208 @default.
• W2161844504 hasAuthorship W2161844504A5066894053 @default.
• W2161844504 hasAuthorship W2161844504A5068834306 @default.
• W2161844504 hasAuthorship W2161844504A5070096873 @default.
• W2161844504 hasAuthorship W2161844504A5083279961 @default.
• W2161844504 hasConcept C126322002 @default.
• W2161844504 hasConcept C141071460 @default.
• W2161844504 hasConcept C143998085 @default.
• W2161844504 hasConcept C2776364478 @default.
• W2161844504 hasConcept C2777408962 @default.
• W2161844504 hasConcept C2778822529 @default.
• W2161844504 hasConcept C2779134260 @default.
• W2161844504 hasConcept C2779695342 @default.
• W2161844504 hasConcept C2779972918 @default.
• W2161844504 hasConcept C28328180 @default.
• W2161844504 hasConcept C2911091166 @default.
• W2161844504 hasConcept C54355233 @default.
• W2161844504 hasConcept C71924100 @default.
• W2161844504 hasConcept C86803240 @default.
• W2161844504 hasConcept C90924648 @default.
• W2161844504 hasConceptScore W2161844504C126322002 @default.
• W2161844504 hasConceptScore W2161844504C141071460 @default.
• W2161844504 hasConceptScore W2161844504C143998085 @default.
• W2161844504 hasConceptScore W2161844504C2776364478 @default.
• W2161844504 hasConceptScore W2161844504C2777408962 @default.
• W2161844504 hasConceptScore W2161844504C2778822529 @default.
• W2161844504 hasConceptScore W2161844504C2779134260 @default.
• W2161844504 hasConceptScore W2161844504C2779695342 @default.

• next